Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells $72,117.16 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn sold 3,061 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $23.56, for a total transaction of $72,117.16. Following the completion of the sale, the chief financial officer owned 88,935 shares in the company, valued at approximately $2,095,308.60. This represents a 3.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Howard Horn also recently made the following trade(s):

• On Wednesday, December 10th, Howard Horn sold 3,081 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $36.38, for a total transaction of $112,086.78.

Ultragenyx Pharmaceutical Trading Down 3.6%

Shares of NASDAQ:RARE opened at $23.79 on Friday. The firm’s 50 day moving average is $28.32 and its two-hundred day moving average is $29.89. The firm has a market capitalization of $2.30 billion, a P/E ratio of -4.01 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.41 and a 52 week high of $46.50.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The business had revenue of $159.93 million during the quarter, compared to the consensus estimate of $167.42 million. During the same period last year, the company earned ($1.40) earnings per share. The business’s quarterly revenue was up 14.6% compared to the same quarter last year. Analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Institutional Trading of Ultragenyx Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Assetmark Inc. boosted its holdings in Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,024 shares in the last quarter. Huntington National Bank lifted its position in shares of Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 393 shares during the last quarter. Danske Bank A S bought a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth $39,000. Smartleaf Asset Management LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 205.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 1,169 shares during the last quarter. Finally, Covestor Ltd raised its position in shares of Ultragenyx Pharmaceutical by 26.0% during the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 369 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on RARE shares. Barclays cut their price objective on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, November 24th. Wells Fargo & Company dropped their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 30th. Leerink Partners reduced their price target on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Tuesday, December 30th. Robert W. Baird lowered their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 30th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday. Sixteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $72.29.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Late‑stage gene‑therapy data: Reports say Ultragenyx’s gene therapy showed sustained improvements in MPS IIIA, a positive clinical read that supports long‑term value of the pipeline. Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA
• Positive Sentiment: Analyst support: HC Wainwright reiterated a “Buy” rating on RARE, which may provide baseline demand from investors who follow the firm. HC Wainwright Reiterates “Buy” Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)
• Neutral Sentiment: Upcoming earnings: Ultragenyx is scheduled to report quarterly results shortly; previews (and consensus) currently expect continued negative EPS, which heightens sensitivity to the print. Ultragenyx Pharmaceutical (RARE) to Release Earnings on Thursday
• Neutral Sentiment: Insider activity: CFO Howard Horn sold ~3,061 shares (~$72k) in early February — a modest reduction in his stake that investors may note but that is not large enough, by itself, to imply a governance crisis. SEC filing: Insider sale disclosure
• Negative Sentiment: Multiple class‑action suits and investigations: Several law firms (Rosen, Bragar Eagel & Squire, Faruqi & Faruqi, Gainey McKenna & Egleston, Holzer & Holzer, Robbins Geller/RGRD and others) have filed or announced investigations alleging that Ultragenyx made false/misleading statements or omitted material facts about expected results and risks for its Phase III Orbit and Cosmic studies (setrusumab). This increases legal risk, potential distraction, and contingent liabilities for the company. Rosen Law Firm investor notice Bragar Eagel & Squire class action alert
• Negative Sentiment: Earnings risk: Analysts and previews (e.g., Zacks) highlight that Ultragenyx lacks the setup for an earnings beat and consensus expects continued losses, so an earnings miss or weak guidance could push shares lower. Zacks earnings preview

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.